This product is for research use only, not for human use. We do not sell to patients.
| Size | Price | Stock |
|---|---|---|
| 100mg | $1950 | To Be Confirmed |
| 200mg | $2925 | To Be Confirmed |
| 500mg | $4935 | To Be Confirmed |
: Cat #: V3915 CAS #: 1535212-07-7 Purity ≥ 98%
Description: Voxilaprevir (formerly GS-9857; GS9857; trade name: Vosevi) is a hepatitis C virus nonstructural protein (HCV NS) 3/4A protease inhibitor developed by Gilead and approved in 2017 as an anti-HCV drug for use in combination with sofosbuvir and velpatasvir.
References: EMA Assessment Report for Sofosbuvir/Velpatasvir/Voxilaprevir
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 868.94 |
|---|---|
| Molecular Formula | C40H52F4N6O9S |
| CAS No. | 1535212-07-7 |
| Storage | -20℃ for 3 years in powder formr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: 10mMr |
| Water: N/Ar | |
| Ethanol: N/A | |
| SMILES Code | COC(C=C1)=CC2=C1N=C(C(O[C@@H](C3)[C@@H](CC)[C@@H](C(N[C@]4(C(NS(=O)(C5(C)CC5)=O)=O)C[C@H]4C(F)F)=O)N3C6=O)=N2)C(F)(F)CCCC[C@H]7[C@@H](C7)OC(N[C@H]6C(C)(C)C)=O |
| Synonyms | GS-9857; GS 9857; GS9857; trade name: Vosevi |
| Protocol | In Vitro | NS3/4A protease is essential for proteolytic cleavage of the HCV encoded polyprotein (intomature forms of NS3, NS4A, NS4B, NS5A and NS5B proteins) and hence for viral replication. In stable cell lines (Huh-7-Lunet or Huh7-1C cells) expressing renilla luciferase-encoding HCV replicons. Voxilaprevir exhibits potent pangenotypic antiviral activity with EC50 ranging from 0.33 to 6.6 nM across genotypes 1 to 6. Voxilaprevir is against HCV replicon strain DQ314805, H77, Con1, JFH-1, J6,J8 (full length) and HM568433, SA13 (NS3 Chimera) with IC50 values of 0.33 nM, 3.9 nM, 3.3 nM, 3.7 nM, 4.5 nM, 1.8 nM, and 6.6 nM, 1.9 nM, respectively. In enzymatic assays using recombinant NS3 protease domains and isogenic NS4A peptide cofactors provided in trans. Voxilaprevir is against HCV genotype 1b and 3a NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively. |
|---|
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 1.1508 mL | 5.7541 mL | 11.5083 mL | 23.0165 mL |
| 5mM | 0.2302 mL | 1.1508 mL | 2.3017 mL | 4.6033 mL |
| 10mM | 0.1151 mL | 0.5754 mL | 1.1508 mL | 2.3017 mL |
| 20mM | 0.0575 mL | 0.2877 mL | 0.5754 mL | 1.1508 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.